|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001563,
umls-concept:C0016360,
umls-concept:C0030705,
umls-concept:C0036525,
umls-concept:C0123931,
umls-concept:C0138837,
umls-concept:C0205269,
umls-concept:C0282460,
umls-concept:C0759338,
umls-concept:C1442162,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1532411,
umls-concept:C1550718
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-8-14
|
|
pubmed:abstractText |
ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BaurHH,
pubmed-author:HollywoodEE,
pubmed-author:IlsonDD,
pubmed-author:KelsenD PDP,
pubmed-author:KemenyNN,
pubmed-author:O'ReillyEE,
pubmed-author:SaltzL BLB,
pubmed-author:SharmaSS,
pubmed-author:StatkevichPP,
pubmed-author:ZaknoenSS,
pubmed-author:ZinAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1067-71
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12176785-Administration, Oral,
pubmed-meshheading:12176785-Adult,
pubmed-meshheading:12176785-Aged,
pubmed-meshheading:12176785-Aged, 80 and over,
pubmed-meshheading:12176785-Biopsy, Needle,
pubmed-meshheading:12176785-Colorectal Neoplasms,
pubmed-meshheading:12176785-Dose-Response Relationship, Drug,
pubmed-meshheading:12176785-Drug Administration Schedule,
pubmed-meshheading:12176785-Drug Resistance,
pubmed-meshheading:12176785-Drug Resistance, Neoplasm,
pubmed-meshheading:12176785-Enzyme Inhibitors,
pubmed-meshheading:12176785-Female,
pubmed-meshheading:12176785-Fluorouracil,
pubmed-meshheading:12176785-Follow-Up Studies,
pubmed-meshheading:12176785-Humans,
pubmed-meshheading:12176785-Liver Neoplasms,
pubmed-meshheading:12176785-Lung Neoplasms,
pubmed-meshheading:12176785-Male,
pubmed-meshheading:12176785-Middle Aged,
pubmed-meshheading:12176785-Neoplasm Staging,
pubmed-meshheading:12176785-Piperidines,
pubmed-meshheading:12176785-Pyridines,
pubmed-meshheading:12176785-Survival Analysis,
pubmed-meshheading:12176785-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
|
|
pubmed:affiliation |
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 11201, USA. sharma1@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
